welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
This is a Study to Get More Information About Non Ambulatory Boys & Men With Duchenne Muscular Dystrophy
study id #: NCT01098708
condition: Duchenne Muscular Dystrophy
Many therapeutic trials in DMD exclude non-ambulatory boys and men. Rate of progression in these non-ambulatory patients has been studied but consensus has not been reached for what measures are most reliable and reproducible. Furthermore, any treatment trial would be expected to demonstrate improved function and improvement in quality of life. Therefore, function, strength, and quality of life must be understood and standardized. While the goal of this proposal is to standardize clinical outcomes for therapeutic trials, careful understanding of the progression of DMD in non ambulatory boys may also lead to better medical treatment.
mechanism of action: No pharmaceutical intervention
start date: March 2010
estimated completion: November 2013
size / enrollment: 50
study description: For Non-ambulatory study, boys must be unable to walk without assistive devices for greater than or equal to one year.
Age at onset of study for non-ambulatory boys and men: greater than or equal to 7 years through age 22 years.
Genetic or biopsy confirmation of dystrophinopathy or clinical diagnosis of DMD with biopsy/genetic confirmation in a primary relative.
- Dystrophin gene mutations that predispose to early onset cardiomyopathy [ Time Frame: 3 years ]
• For Non-ambulatory study, boys must be unable to walk without assistive devices for greater than or equal to one year.
• Age at onset of study for non-ambulatory boys and men: greater than or equal to 7 years through age 22 years.
• Genetic or biopsy confirmation of dystrophinopathy or clinical diagnosis of DMD with biopsy/genetic confirmation in a primary relative.
For Non-ambulatory study, the inability to understand and cooperate with the testing would exclude a subject.
Gait deviations in Duchenne muscular dystrophy-Part 1. A systematic reviewBackground: Although prolonged ambulati...
Evaluation of Muscle miRNA as Biomarkers in DystrophinopathiesDuchenne muscular dystrophy (DMD), cause...
Effect of Muscle Strength on Hamstring Flexibility in Children With Duchenne Muscular DystrophyInvestigator researched that the effect ...
Ketoacidosis in Duchenne muscular dystrophy: A report on 4 casesThe longer survival in Duchenne dystroph...
The relationship of body habitus and respiratory function in Duchenne muscular dystrophyBackground: The multidisciplinary care ...
PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical TrialPTC Therapeutics, Inc. is seeking pati...
Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial...Sarepta Therapeutics, Inc., a commercia...